NeurOp

NeurOp is a private, clinical-stage biotech leveraging deep expertise in NMDA receptor pharmacology to develop novel treatments for severe CNS conditions. Founded by leading academic neuroscientists from Emory and Duke, the company has advanced its lead compound, NP10679, into Phase 1 trials with initial targets of peri-operative pain and subarachnoid hemorrhage, the latter having received FDA Orphan Drug Designation. NeurOp operates with a lean, advisor-supported model, focusing on precise subunit targeting of the NMDA receptor to improve efficacy and safety over previous non-selective approaches in this challenging target class.

Design of small molecules that selectively target specific subunits of the NMDA (N-methyl-D-aspartate) receptor to modulate pathological activity while minimizing side effects associated with broad receptor antagonism.

The NMDA receptor target is well-known but challenging, with past failures of non-selective drugs. NeurOp competes with numerous companies developing non-opioid analgesics and neuroprotective agents across different mechanisms. Its subunit-selective approach aims to differentiate on safety and efficacy.